Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,474 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
Park JH, Chun SH, Lee YG, Chang H, Lee KW, Kim HR, Shin SH, An HJ, Lee KE, Hwang IG, Ahn MJ, Kim SB, Keam B. Park JH, et al. Among authors: lee ke, lee kw, lee yg. J Cancer Res Clin Oncol. 2020 Dec;146(12):3359-3369. doi: 10.1007/s00432-020-03316-5. Epub 2020 Jul 15. J Cancer Res Clin Oncol. 2020. PMID: 32671504
Current Status and Challenges of Cancer Clinical Trials in Korea.
Shim BY, Park SH, Lee S, Kim JS, Lee KE, Kang YK, Ahn MJ. Shim BY, et al. Among authors: lee ke, lee s. Cancer Res Treat. 2016 Jan;48(1):20-7. doi: 10.4143/crt.2014.317. Epub 2015 Mar 2. Cancer Res Treat. 2016. PMID: 25761486 Free PMC article.
Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
Kim Y, Lee SJ, Lee JY, Lee SH, Sun JM, Park K, An HJ, Cho JY, Kang EJ, Lee HY, Kim J, Keam B, Kim HR, Lee KE, Choi MY, Lee KH, Ahn MJ. Kim Y, et al. Among authors: lee sh, lee sj, lee ke, lee kh, lee jy, lee hy. Cancer. 2017 Jun 1;123(11):1958-1964. doi: 10.1002/cncr.30537. Epub 2017 Jan 19. Cancer. 2017. PMID: 28102887 Free article. Clinical Trial.
Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).
Jung M, Ryu MH, Oh DY, Kang M, Zang DY, Hwang IG, Lee KW, Kim KH, Shim BY, Song EK, Sym SJ, Han HS, Park YL, Kim JS, Lee HW, Lee MH, Koo DH, Song HS, Lee N, Yang SH, Choi DR, Hong YS, Lee KE, Maeng CH, Baek JH, Kim S, Kim YH, Rha SY, Cho JY, Kang YK. Jung M, et al. Among authors: lee mh, lee ke, lee kw, lee hw, lee n. Gastric Cancer. 2018 Sep;21(5):819-830. doi: 10.1007/s10120-018-0806-1. Epub 2018 Feb 9. Gastric Cancer. 2018. PMID: 29427038 Clinical Trial.
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH, Kim TY, Kim GM, Kang SY, Park IH, Kim JH, Lee KE, Ahn HK, Lee MH, Kim HJ, Kim HJ, Lee JI, Koh SJ, Kim JY, Lee KH, Sohn J, Kim SB, Ahn JS, Im YH, Jung KH, Im SA; Korean Cancer Study Group (KCSG). Park YH, et al. Among authors: lee mh, lee ke, lee kh, lee ji. Lancet Oncol. 2019 Dec;20(12):1750-1759. doi: 10.1016/S1470-2045(19)30565-0. Epub 2019 Oct 24. Lancet Oncol. 2019. PMID: 31668850 Clinical Trial.
Correction to: Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
Park JH, Chun SH, Lee YG, Chang H, Lee KW, Kim HR, Shin SH, An HJ, Lee KE, Hwang IG, Ahn MJ, Kim SB, Keam B. Park JH, et al. Among authors: lee ke, lee kw, lee yg. J Cancer Res Clin Oncol. 2020 Dec;146(12):3371. doi: 10.1007/s00432-020-03342-3. J Cancer Res Clin Oncol. 2020. PMID: 32852636
1,474 results